Results of a phase 3 clinical trial show an experimental drug called tolebrutinib can delay disability in patients with non-relapsing secondary progressive multiple sclerosis.
Health News is provided as a service to Main Discount Drug Center site users by HealthDay. Main Discount Drug Center nor its employees, agents, or contractors, review, control, or take responsibility for the content of these articles. Please seek medical advice directly from your pharmacist or physician.